Literature DB >> 19225844

Surgery for recurrent ovarian cancer: role of peritoneal carcinomatosis: exploratory analysis of the DESKTOP I Trial about risk factors, surgical implications, and prognostic value of peritoneal carcinomatosis.

P Harter1, M Hahmann, H J Lueck, M Poelcher, P Wimberger, O Ortmann, U Canzler, B Richter, U Wagner, A Hasenburg, A Burges, S Loibl, W Meier, J Huober, D Fink, W Schroeder, K Muenstedt, B Schmalfeldt, G Emons, A du Bois.   

Abstract

BACKGROUND: Almost all retrospective trials pointed out that a benefit of surgery for recurrent ovarian cancer may be limited to patients in whom a macroscopic complete resection could be achieved. Peritoneal carcinomatosis has been reported to be either a negative predictor for resectability or a negative prognostic factor, or both. The role of peritoneal carcinomatosis in a multicenter trial was investigated.
METHODS: Exploratory analysis of the DESKTOP I trial (multicenter trial of patients undergoing surgery for recurrent ovarian cancer, 2000 to 2003).
RESULTS: A total of 125 patients (50%) who underwent surgery for recurrent ovarian cancer had peritoneal carcinomatosis. Univariate analyses showed worse overall survival for patients with peritoneal carcinomatosis compared with patients without carcinomatosis (P < .0001). Patients with and without peritoneal carcinomatosis had a complete resection rate of 26% and 74%, respectively (P < .0001). This corresponded with the observation that patients with complete resection had a better prognosis than those with minimal residual disease of 1 to 5 mm, which commonly reflects peritoneal carcinomatosis (P = .0002). However, patients who underwent complete resection, despite peritoneal carcinomatosis, had a 2-year survival rate of 77%, which was similar to the 2-year survival rate of patients with completely debulked disease who did not have peritoneal carcinomatosis (81%) (P = .96). Analysis of prognostic factors did not show any independent effect of peritoneal carcinomatosis on survival in patients who underwent complete resection.
CONCLUSIONS: Peritoneal carcinomatosis was a negative predictor for complete resection but had no effect on prognosis if complete resection could be achieved. Improving surgical skills might be one step to increase the proportion of patients who might benefit from surgery for recurrent disease.

Entities:  

Mesh:

Year:  2009        PMID: 19225844     DOI: 10.1245/s10434-009-0357-0

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  29 in total

1.  The role of secondary cytoreductive surgery in patients with recurrent epithelial ovarian, tubal, and peritoneal cancers: a comparative effectiveness analysis.

Authors:  Chi-Mu Chuang; Yiing-Jeng Chou; Ming-Shyen Yen; Kuan-Chong Chao; Nae-Fang Twu; Hua-Hsi Wu; Kuo-Chang Wen; Yi-Jen Chen; Peng-Hui Wang; Chung-Ru Lai; Pesus Chou
Journal:  Oncologist       Date:  2012-05-16

Review 2.  The role of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the treatment of ovarian cancer relapse.

Authors:  E Saladino; F Fleres; S Irato; C Famulari; A Macrì
Journal:  Updates Surg       Date:  2013-08-27

Review 3.  Treatment options in recurrent ovarian cancer: latest evidence and clinical potential.

Authors:  Daniela Luvero; Andrea Milani; Jonathan A Ledermann
Journal:  Ther Adv Med Oncol       Date:  2014-09       Impact factor: 8.168

4.  Nodal status--its impact on prognosis in advanced ovarian cancer.

Authors:  C Bachmann; S Bachmann; T Fehm; A Staebler; S Becker; R Rothmund; C Gardanis; E M Grischke; D Wallwiener; E F Solomayer
Journal:  J Cancer Res Clin Oncol       Date:  2011-11-22       Impact factor: 4.553

5.  Survival Impact of Secondary Cytoreductive Surgery for Recurrent Ovarian Cancer in an Asian Population.

Authors:  Rani Akhil Bhat; Yin Nin Chia; Yong Kuei Lim; Kwai Lam Yam; Cindy Lim; Melissa Teo
Journal:  Oman Med J       Date:  2015-09

Review 6.  Recurrent ovarian cancer: when and how to treat.

Authors:  Marcia Hall; Gordon Rustin
Journal:  Curr Oncol Rep       Date:  2011-12       Impact factor: 5.075

Review 7.  [Surgical treatment of peritoneal metastases from gynecological primary tumors].

Authors:  P Horvath; A Königsrainer
Journal:  Chirurg       Date:  2018-09       Impact factor: 0.955

8.  Statement by the Kommission OVAR of the AGO Study Group on the Use of HIPEC (Hyperthermic Intraperitoneal Chemotherapy) to Treat Primary and Recurrent Ovarian Cancer.

Authors:  P Harter; S Mahner; F Hilpert; I Runnebaum; O Ortmann; A Mustea; J Sehouli; A du Bois; U Wagner
Journal:  Geburtshilfe Frauenheilkd       Date:  2013-03       Impact factor: 2.915

9.  Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in recurrent epithelial ovarian cancer with peritoneal metastases: a single centre experience.

Authors:  Ingmar Königsrainer; Philipp Horvath; Florian Struller; Eva Maria Grischke; Diethelm Wallwiener; Alfred Königsrainer; Stefan Beckert
Journal:  Langenbecks Arch Surg       Date:  2014-05-11       Impact factor: 3.445

10.  Partial Cystectomy for Atypical Isolated Recurrence of Ovarian Adenocarcinoma - A Case Report and Literature Review.

Authors:  Nicolae Bacalbasa; Irina Balescu
Journal:  In Vivo       Date:  2017 May-Jun       Impact factor: 2.155

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.